Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database

Qing-Xia Chen¹,*, Jun-Jing Li¹,*, Xiao-Xiao Wang¹,*, Pei-Yang Lin¹, Jie Zhang¹, Chuan-Gui Song¹, Zhi-Ming Shao²

¹Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, China
²Department of Breast Surgery, Key Laboratory of Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China

*These authors contributed equally to this work

Correspondence to: Chuan-Gui Song, email: songchuangui@yahoo.com

Keywords: adenoid cystic carcinoma, invasive ductal carcinoma, breast cancer-specific survival, overall survival

Received: August 02, 2016 Accepted: December 12, 2016 Published: December 20, 2016

ABSTRACT

Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and indolent tumor with a good prognosis despite its triple-negative status. However, we observed different outcomes in the present study. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we enrolled a total of 89,937 eligible patients with an estimated 86 breast-ACC cases and 89,851 invasive ductal carcinoma (IDC) patients. In our study, breast-ACC among women presented with a higher proportion of triple-negative breast cancer (TNBC), which was more likely to feature well-differentiated tumors, rare regional lymph node involvement and greater application of breast-conserving surgery (BCS). Kaplan-Meier analysis revealed that patients with breast-ACC and breast-IDC patients had similar breast cancer-specific survival (BCSS) and overall survival (OS). Moreover, using the propensity score matching method, no significant difference in survival was observed in matched pairs of breast-ACC and breast-IDC patients. Additionally, BCSS and OS did not differ significantly between TNBC-ACC and TNBC-IDC after matching patients for age, tumor size, and nodal status. Further subgroup analysis of molecular subtype indicated improved survival in breast-ACC patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/Her2-) tumors compared to IDC patients with HR+/Her2- tumors. However, the survival of ACC-TNBC and IDC-TNBC patients was similar. In conclusion, ACCs have an indolent clinical course and result in similar outcomes compared to IDC. Understanding these clinical characteristics and outcomes will endow doctors with evidence to provide the same intensive treatment for ACC-TNBC as for IDC-TNBC and lead to more individualized and tailored therapies for breast-ACC patients.

INTRODUCTION

Invasive breast cancers are a heterogeneous group of tumors that exhibit wide variation in their clinical presentation, behavior, and morphological spectrum [1]. Clinicians have designed different treatment plans for patients based on predictive and prognostic factors. To treat patients with heterogeneous cancer, it is critical to understand the specific biological characteristics associated with the prognosis and outcomes of a given histological type. Approximately 83% of invasive breast cancers are classified as invasive ductal carcinoma, not otherwise specified (IDC-NOS) [2, 3], whereas approximately 0.1%~1% are defined as adenoid cystic carcinoma (ACC) [1, 3]. Based on its clinicopathological characteristics and outcomes, ACC is distinct from IDC-NOS.
ACC is a rare malignancy of exocrine glands defined by the presence of a dual population of cells, and identical tumors can also arise from the breast. The unique characteristics of breast-ACC include a lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and HER2 and a basal-like phenotype in transcriptomic analysis [1, 4, 5]. However, HR+ breast-ACC has been reported [6, 7]. In contrast to the poor prognosis associated with other triple-negative breast cancers (TNBCs), ACC has been reported to exhibit a favorable prognosis and less aggressive behavior [8, 9], including a predominance among females and whites, a high percentage of low-grade tumors, localized stage tumors, absence of regional lymph node involvement, greater use of breast-conserving surgery (BCS), and lower use of chemotherapy [8, 9]. The 5-year overall and disease-free survival rates of breast-ACC are 94% and 82%, respectively [10]. However, ACC of the breast has been assigned a poor outcome based on a 70-gene poor prognosis profile and 21-gene high-risk recurrence score [1, 11, 12].

Due to its rarity, there are currently no established guidelines for treating this type of cancer, and there are large variations in patterns of practice. With respect to survival, BCS including postoperative radiotherapy (RT) appears to be equivalent to mastectomy alone [10, 13]. However, a Rare Cancer Network study reported that postoperative RT improved 5-year locoregional control (LRC) rates from 83% to 95% and that BCS is the treatment of choice for patients with ACC breast cancer [10]. The literature has increasingly recommended that BCS should be considered for ACC unless the tumor is large or the axillary lymph nodes are involved [14]. Accordingly, recent studies have reported a higher rate of patients treated with lumpectomy [6, 14, 15].

The identification of prognostic factors might enable more precise therapies for ACC patients. However, the effects of molecular subtype have not been investigated thoroughly in large population-based studies. Based on HER2 status recorded in the SEER database after 2010, the present study is the first to specifically provide insight into the effects of molecular subtype on breast-ACC outcomes compared to invasive ductal carcinoma of the breast (breast-IDC). Long-term survival has been calculated in the SEER database, with 5-year, 10-year, and 15-year relative survivals of 98.1%, 94.9%, and 91.4%, respectively [8]. Because an early peak of recurrence for the TNBC subtype occurs within the first 2–3 years after diagnosis, we conducted a short-term survival comparison between breast-ACC and breast-IDC, similar to a previous study of medullary breast carcinoma [16] and invasive cribriform carcinoma [17], and aimed to identify the differences in characteristics and outcomes between ACC and IDC with a large population-based dataset. Surprisingly, our conclusions based on the comparison of ACC and IDC are distinct from those of previous studies.

**RESULTS**

**Demographics and clinical characteristics of the study population**

Overall, 89,937 eligible patients were enrolled in our study, including 86 cases of breast-ACC and 89,851 cases of breast-IDC. The median follow-up time was 22 months. The baseline characteristics of the breast-ACC and breast-IDC subtypes are summarized in Table 1. There were significant differences in characteristics between the two subtypes, including grade, American Joint Committee on Cancer (AJCC) stage, tumor size, nodal status, breast subtype and type of surgery. Breast-ACC patients presented a higher proportion of TNBC (77.9% vs. 12.8%, P < 0.001), lower grade (grade I, 54.7% vs. 21.5%, P < 0.001), earlier stage (AJCC stage III, 0.0% vs. 9.0%, P = 0.007), and lower likelihood of nodal involvement (97.7% vs. 69.9%, P < 0.001). In addition, breast-ACC patients were more inclined to accept BCS than IDC patients (77.9% vs. 60.8, P = 0.001). Other tumor characteristics, including age, race, marital status, laterality, tumor size and radiation therapy, were similarly distributed between the two histological types.

**Comparison of survival between breast-ACC and breast-IDC**

Figure 1 presents the survival curves of the two histological types for breast cancer-specific survival (BCSS) and overall survival (OS) depicted using the Kaplan-Meier method. BCSS (P = 0.457) and OS (P = 0.126) were similar for these two histological types. Supplementary Table S1 and Table 2 summarize the prognostic factors according to the BCSS and OS results from univariate and multivariate Cox proportional hazard regression models, respectively. Many factors, including being black or unmarried, poor differentiation, advance stage, larger tumor size, increased number of lymph nodes, subtype of TNBC, mastectomy treatment and no radiation therapy, were significantly associated with poor BCSS and OS in univariate analysis. However, after adjusting for other prognostic factors via multivariate analysis, AJCC stage and type of surgery were no longer independent prognostic factors for OS. In addition, breast-ACC patients exhibited similar BCSS (univariate: hazard ratio (HR) = 1.357, 95% confidence interval, CI: 0.339–5.430, P = 0.666; multivariate: HR = 1.757, 95% CI: 0.820–7.060, P = 0.327) and OS (univariate: HR = 1.216, 95% CI: 0.456–3.241, P = 0.696, multivariate: HR = 1.127 (0.422–3.014), 95% CI: 0.422–3.014, P = 0.811) compared to IDC patients after univariate and multivariate analysis.

**Survival estimates in matched groups**

We conducted 1:1 (breast-ACC/breast-IDC) matched case-control analysis using a propensity score
matching method and a comprehensive consideration of the confounding factors affecting breast cancer outcomes between breast-ACC and breast-IDC patients (Table 3). Finally, we obtained a group of 172 patients, and each counterpart included 86 patients. For the matched groups, with the exception of grade and type of surgery, no factors differed significantly between breast-ACC and breast-IDC. Furthermore, we validated that IDC histology has the same prognostic value for breast-ACC patients with respect to BCSS or OS (Figure 2, $P = 0.966$ and $P = 0.679$ for BCSS and OS, respectively).

**Baseline characteristics and survival outcomes in the triple-negative subgroup**

Overall, 77.9% of breast-ACC patients were diagnosed with TNBC. To obtain deeper insight into the breast-ACC cases, we further investigated the characteristics and survival outcomes of the patients in the TNBC subgroup, which included 67 ACC patients and 11,534 IDC patients (Supplementary Table S2). When the entire population was considered, TNBC-ACC patients tended to be well-differentiated (grade I, 52.2% vs. 1.4%, $P < 0.001$), to be at an earlier stage (AJCC stage III, 0.0% vs. 11.6%, $P = 0.005$), to have a lower likelihood for nodal involvement (98.9% vs. 68.7%, $P < 0.001$), and to receive BCS (76.1% vs. 54.7%, $P = 0.001$). Kaplan-Meier curves revealed similar BCSS and OS for TNBC-ACC patients and TNBC-IDC patients (Figure 3, $P = 0.198$ and $P = 0.297$ for BCSS and OS, respectively). Furthermore, there were no significant differences in BCSS and OS for the 67 TNBC-ACC patients and 67 TNBC-IDC patients matched using the propensity score matching method (Figure 4, $P = 0.152$ and $P = 0.348$ for BCSS and OS, respectively).

**Stratification analysis with molecular subtype**

We stratified molecular subtype to further validate the different outcomes affected by molecular subtype between breast-ACC and breast-IDC cases. As shown in Table 4, multivariate analysis revealed excellent survival for HR+/Her2- patients with breast-ACC compared to HR+/Her2- patients with breast-IDC according to BCSS (HR: 35.244, 95% CI: 4.912–252.871, $P < 0.001$) and OS (HR: 16.137, 95% CI: 4.020–64.776, $P < 0.001$) for breast-ACC patients. However, survival was similar for ACC-TNBC and IDC-TNBC patients. These findings suggest that we can not neglect this molecular subtype when formulating therapies for breast-ACC patients.

**DISCUSSION**

Using this large amount of population-based data, we aimed to analyze the characteristics and outcomes of breast-ACC patients compared to breast-IDC patients. Our findings indicate that breast-ACC has distinct clinical and pathological characteristics and exhibits an indolent clinical course compared to breast-IDC. However, we did not observe improved survival for breast-ACC compared to breast-IDC after adjusting and matching confounding factors. Moreover, further subgroup analysis of molecular subtypes revealed improved survival in breast-ACC patients with HR+/Her2- compared to breast-IDC patients with HR+/Her2-, whereas survival was similar for ACC-TNBC and IDC-TNBC.

Kulkarni et al. [9] compared breast-ACC and breast-IDC using national cancer data and observed distinct differences in median tumor size, histological grade, node positive rate, BCS type, and hormone therapy.

**Figure 1:** Kaplan–Meier curves of breast cancer-specific survival (BCSS, **A**) and overall survival (OS, **B**) based on histology for all patients, adenoid cystic carcinoma (ACC) vs. invasive ductal carcinoma (IDC).
between the two tumor types. Slightly larger tumor size, more cases of grade I, a lower rate of node positivity, more BCS and less hormone therapy were observed for breast-ACC. Similarly, in our study, breast-ACC patients presented with a higher proportion of TNBC and were more likely to have well-differentiated tumors, a less advanced stage, and rare regional lymph node involvement; compared to the breast-IDC group, more of
these patients received BCS. Accordingly, we inferred that breast-ACC patients have unique clinical and pathological characteristics and that the disease was inclined to more indolent behavior in these patients.

Favorable prognosis for breast-ACC has already been demonstrated [18]. Although there was no significant difference in survival for grade 1 and stage 1 patients when comparing breast-ACC and breast-IDC, Kulkarni et al. [9] observed better 5-year overall survival in breast-ACC when compared to breast-IDC in the entire cohort, indicating that the increased OS may largely be explained by the lower grade and earlier stage of patients presenting with the former compared to the latter. However, in our study, the histology type was not a surrogate for better survival in breast-ACC and breast-IDC patients. Instead, older age, black race, unmarried, higher grade, larger tumor size, a more positive nodal status, TNBC subtype and no radiation therapy were significantly associated with poor BCSS and OS.

Although most breast-ACC cases are HR-, rare HR+ cases have been reported [8–10]. When referring to molecular subtype, no complete information in a related large population-based study has been observed. To further

**Figure 2:** Kaplan–Meier curves of breast cancer-specific survival (BCSS, A) and overall survival (OS, B) by histology for 1:1 matched group, adenoid cystic carcinoma (ACC) vs. invasive ductal carcinoma (IDC).

**Figure 3:** Kaplan–Meier curves of breast cancer-specific survival (BCSS, A) and overall survival (OS, B) based on histology for triple-negative breast cancer (TNBC) patients, adenoid cystic carcinoma (ACC) vs. invasive ductal carcinoma (IDC).
investigate probable prognostic factors, we conducted a short-term survival comparison between breast-ACC and breast-IDC patients based on molecular subtype. To our surprise, our results differed from those of previous studies. We observed similar survival among patients with breast-ACC compared to breast-IDC, and this result was validated by a propensity score matching method. Additionally, BCSS and OS did not differ significantly between TNBC-ACC and TNBC-IDC before and after matching based on age, tumor size, and nodal status. Subgroup

Table 2: Multivariate cox proportional hazard model of breast cancer-specific survival (BCSS) and overall survival (OS)

| Variables          | BCSS  | OS   |
|--------------------|-------|------|
|                    | HRs (95% CI) | P  | HRs (95% CI) | P  |
| Age (years)        |       |      |              |    |
| 20–49              | 0.778 (0.693–0.873) | < 0.001 | 0.605 (0.547–0.669) | < 0.001 |
| 50–79              | Reference |      | Reference |      |
| Race               |       |      |              |    |
| White              | Reference |      | Reference |      |
| Black              | 1.232 (1.077–1.408) | 0.002 | 1.218 (1.090–1.360) | < 0.001 |
| Other*             | 0.675 (0.542–0.840) | < 0.001 | 0.723 (0.610–0.857) | < 0.001 |
| Marital status     |       |      |              |    |
| Married            | Reference |      | Reference |      |
| Not marriedb       | 1.254 (1.125–1.397) | < 0.001 | 1.500 (1.377–1.634) | < 0.001 |
| Grade              |       |      |              |    |
| I                  | 0.337 (0.226–0.502) | < 0.001 | 0.884 (0.747–1.046) | 0.150 |
| II                 | Reference |      | Reference |      |
| III and IV         | 2.230 (1.926–2.581) | < 0.001 | 1.612 (1.447–1.795) | < 0.001 |
| Histology type     |       |      |              |    |
| ACC                | 2.548 (0.633–10.253) | 0.188 | 2.225 (0.830–5.966) | 0.112 |
| IDC                | Reference |      | Reference |      |
| AJCC stage         |       |      |              |    |
| I                  | Reference |      | Reference |      |
| II                 | 1.542 (1.200–1.980) | 0.001 | 1.115 (0.924–1.344) | 0.256 |
| III                | 1.740 (1.180–2.565) | 0.005 | 1.199 (0.863–1.667) | 0.280 |
| Tumor size (cm)    |       |      |              |    |
| ≤ 2                | Reference |      | Reference |      |
| > 2 and ≤ 5        | 1.655 (1.371–1.998) | < 0.001 | 1.571 (1.346–1.834) | < 0.001 |
| > 5                | 3.135 (2.477–3.968) | < 0.001 | 2.799 (2.285–3.428) | < 0.001 |
| Nodal status       |       |      |              |    |
| 0                  | Reference |      | Reference |      |
| 1 to 3             | 1.829 (1.562–2.141) | < 0.001 | 1.550 (1.368–1.756) | < 0.001 |
| 4 to 10            | 3.316 (2.413–4.558) | < 0.001 | 2.783 (2.092–3.701) | < 0.001 |
| > 10               | 5.758 (4.231–7.835) | < 0.001 | 4.500 (3.405–5.947) | < 0.001 |
| Breast subtype     |       |      |              |    |
| HR+/Her2-          | Reference |      | Reference |      |
| HR+/Her2+          | 0.620 (0.498–0.771) | < 0.001 | 0.706 (0.600–0.831) | < 0.001 |
| HR-/Her2+          | 1.204 (0.977–1.485) | 0.082 | 1.107 (0.928–1.319) | 0.259 |
| Triple negative    | 3.084 (2.718–3.498) | < 0.001 | 2.440 (2.196–2.710) | < 0.001 |
| Type of surgery    |       |      |              |    |
| BCS                | Reference |      | Reference |      |
| Mastectomy         | 1.137 (1.005–1.286) | 0.041 | 0.992 (0.900–1.094) | 0.875 |
| Radiation          |       |      |              |    |
| No                 | 1.492 (1.332–1.671) | < 0.001 | 1.829 (1.667–2.006) | < 0.001 |
| Yes                | Reference |      | Reference |      |

Abbreviations: AJCC, American Joint Committee on Cancer; ACC, adenoid cystic carcinoma; IDC, invasive ductal carcinoma; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; BCS, breast-conserving surgery; HRs, hazard ratios; CI, confidence interval; BCSS, breast cancer-specific survival; OS, overall survival.

*aOther includes American Indian/Alaskan native, and Asian/Pacific Islander.

*bNot married includes divorced, separated, single (never married), unmarried or domestic partner and widowed.

**P value was adjusted by multivariate Cox proportional hazard regression model including all factors, as categorized in Table 2, and bold type indicates significance.
analyses revealed similar survival for ACC-TNBC and IDC-TNBC; however, excellent survival was observed in HR+/Her2- breast-ACC patients compared to HR+/Her2- patients with breast-IDC. Accordingly, we recognized that the distinct prognostic outcomes are driven in part by the molecular subtype of breast cancer.

Compared to other studies of breast-ACC, our investigation has two major advantages. First, we used
HR and HER2 information and demonstrated survival outcomes in detail according to the molecular subtype in a related large population dataset. Second, we conducted propensity score matching to diminish the effects of confounding factors, which guaranteed more persuasive statistical analyses. Unfortunately, due to the limitations of the SEER database, we did not have information on Ki-67 expression to further subdivide the molecular subtype. Additionally, information on adjuvant chemotherapy and endocrine therapy was not available for our study, which may conceal important prognostic factors affecting the outcomes of cancer. Due to the lack of HER2 status information before 2010, we focused on short-term survival, and the inadequate follow-up time may have

| Subtype          | BCSS          | OS            |
|------------------|---------------|---------------|
|                  | Events No     | HRs (95% CI)  | P  | Events No | HRs (95% CI)  | P   |
| HR+/Her2-        | < 0.001       | 16.137        | 0.001|
| ACC (n = 17)     | 1             | 35.244 (4.912–252.871) |      |
| IDC (n = 63,667) | 546           | Reference     |      |
| HR+/Her2+        | –             | 16.137 (4.020–64.776) |      |
| ACC (n = 0)      | 0             | Reference     |      |
| IDC (n = 10,271) | 97            | Reference     |      |
| HR-/Her2+        | –             | Reference     |      |
| ACC (n = 2)      | 0             | Reference     |      |
| IDC (n = 4,379)  | 111           | Reference     |      |
| Triple negative  | 0.868         | 1.456 (0.353–6.000) | 0.603|
| ACC (n = 67)     | 1             | 0.845 (0.115–6.189) |      |
| IDC (n = 11,534) | 634           | Reference     |      |

Abbreviation: ACC, Adenoid cystic carcinoma; IDC, invasive ductal carcinoma; HR, hormone receptor; Her2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; BCSS, breast cancer-specific survival; OS, overall survival.

*P value was adjusted by a multivariate Cox proportional hazard regression model including age, race, marital status, grade, AJCC stage, tumor size, lymph node status, type of surgery, and radiation, and bold type indicates significance.

Figure 4: Kaplan–Meier curves of breast cancer-specific survival (BCSS, A) and overall survival (OS, B) based on histology for 1:1 matched triple-negative breast cancer (TNBC) patients, adenoid cystic carcinoma (ACC) vs. invasive ductal carcinoma (IDC).
biased the results. However, for the TNBC subtype, an early peak of recurrence occurs within the first 2–3 years after diagnosis [19].

In summary, understanding clinical characteristics and outcomes can provide doctors with evidence to support the same intensive treatment and attention for ACC-TNBC as IDC-TNBC and might lead to more individualized and tailored therapy for breast-ACC patients. However, further subdivision of molecular subtype based on Ki67 expression is needed to validate this conclusion.

MATERIALS AND METHODS

Ethics statement

Because cancer is a reportable disease in every state in the United States, we did not need to obtain patient consent but were required to sign a Data-Use Agreement for the SEER 1973-2013 Research Data File to gain access to the SEER database.

Patients

We used SEER*Stat version 8.3.2. to extract data from the SEER 18 registries research database, including data from 1973 to 2013, and our results generated a case listing with a total of 89,937 eligible patients, including 86 breast-ACC patients and 89,851 breast-IDC patients. In this study, we examined cases of female breast cancer diagnosed with histologically confirmed first invasive breast cancer according to the following criteria: year of diagnosis from 2010 to 2013, age at diagnosis between 20 and 79 years, race, marital status at diagnosis, breast cancer as the first and only malignant cancer, pathologically confirmed ACC (ICD-O-3 8200/3) or IDC-NOS (ICD-O-3 8500/3), unilateral origin of primary cancer, histological grades I to IV, TNM stages I-III, known ER, PR and HER2 status, breast subtype, surgery treatment with either mastectomy or BCS, record of radiation therapy, cause of death, and survival (months). Tumors of any size with direct extension to the chest wall and/or to the skin (T4, including ulceration, skin nodules and inflammatory carcinoma) were not included in the study. To obtain data on HER2 status and ensure adequate follow-up duration, we calculated follow-up times from January 1, 2010, to December 31, 2013.

Outcome measurement

We defined BCSS as the date of diagnosis to the date of death due to breast cancer, and OS was calculated from the date of diagnosis to the date of death regardless of whether the death was related to breast cancer. Patients who were alive were censored on the date of last contact for both outcomes.

Statistical analysis

The chi-square test was employed to describe the demographic and clinical characteristics of the breast-ACC and breast-IDC groups, including the whole group and 1:1 matched group as well as the TNBC group. The Kaplan-Meier method was used to generate survival curves, and the log-rank test was performed to determine whether the differences in BCSS or OS rates between different histological subtypes were statistically significant. A Cox proportional hazards model was utilized to calculate the HR ratio and 95% confidence intervals in the univariate and multivariate analyses and to identify prognostic factors. These statistical analyses were conducted using SPSS version 21.0. To diminish the effects of baseline differences in demographic and clinical characteristics across histology subtypes for outcome differences, we applied the pmatch2 module to perform propensity score matching [20] in Stata version 14.0. The command matched each breast-ACC patient to one breast-IDC patient using the following factors: age, tumor size, nodal status, and breast subtype. All P values were two-sided, and values less than 0.05 were considered statistically significant.

ACKNOWLEDGMENTS AND FUNDING

This study was supported by funding from the Training Plan of Middle-aged and Young Talents of Fujian Province Health and Family Planning Commission (2014-ZQN-ZD-10); the National Key Clinical Specialty Discipline Construction Program.

CONFLICTS OF INTEREST

The authors have declared that no competing interests exist.

REFERENCES

1. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, De Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008; 216:141–50. doi: 10.1002/path.2407.

2. Fakhrjou A, Naghavi- Behzad M, Montazeri V, Karkon-Shayan F, Norouzi-Panahi L, Piri R. The relationship between histologic grades of invasive carcinoma of breast ducts and mast cell infiltration. S Asian J Cancer. 2016; 5:5–7. doi: 10.4103/2278-330X.179699.

3. Alis H, Yigitbas H, Kapan S, Kalayci M, Kilic G, Aygun E. Multifocal adenoid cystic carcinoma of the breast: an unusual presentation. Can J Surg. 2008; 51:E3 6–7. doi:

4. Muslimani AA, Ahiwualia MS, Clark CT, Daw HA. Primary adenoid cystic carcinoma of the breast: case report
and review of the literature. Int Semin Surg Oncol. 2006; 3:17. doi: 10.1186/1477-7800-3-17.
5. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014; 110:565–72. doi: 10.1038/bjc.2013.756.
6. Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer. 2002; 94:2119–27. doi: 10.1002/cncr.10455.
7. Fusco N, Colombo PE, Martelotto LG, De Filippo MR, Piscuoglio S, Ng CK, Lim RS, Jacot W, Vincent-Salomon A, Reis-Filho JS, Weigelt B. Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology. 2016; 68:262–71. doi: 10.1111/his.12735.
8. Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 2010; 12:R54. doi: 10.1186/bcr2613.
9. Kulkarni N, Pezzi CM, Greif JM, Klimberg VS, Bailey L, Korourian S, Zuraek M. Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base. Ann Surg Oncol. 2013; 20:2236–41. doi: 10.1245/s10434-013-2911-z.
10. Khanfir K, Kallel A, Boujelbene N, Khabir A, Boujelbene N, Jeanneret Sozzi W, Mirimanoff RO, Khanfir K. Clinical review–breast adenoid cystic carcinoma. Breast. 2012; 21:124–7. doi: 10.1016/j.breast.2011.11.006.
11. van ’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Taghian AG, Boersma L, Poortmans P. Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012; 82:2118–24. doi: 10.1016/j.ijrobp.2012.10.008.
12. van ’t Veer LJ, Dai H, van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415:530–6. doi: 10.1038/415530a.
13. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014; 110:565–72. doi: 10.1038/bjc.2013.756.
14. Millar BAM, Kerba M, Youngson B, Lockwood GA, Liu FF. The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast. Breast Cancer Res Treat. 2004; 87:225–32. doi: 10.1007/s10549-004-8693-z.
15. Coates JM, Martinez SR, Bold RJ, Chen SL. Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast. J Surg Oncol. 2010; 102:342–7. doi: 10.1002/jso.21638.
16. Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget. 2016; 7:22665–73. doi: 10.18632/oncotarget.8142.
17. Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM. Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast: A SEER population-Based Study. Medicine. 2015; 94:e1309. doi: 10.1097/MD.0000000000001309.
18. Miyai K, Schwartz MR, Divatia MK, Anton RC, Park YW, Ayala AG, Ro JY. Adenoid cystic carcinoma of breast: recent advances. World J Clin Cases. 2014; 2:732–41. doi: 10.12998/wjcc.v2.i12.732.
19. Pogoda K, Niwińska A, Murawska M, Piętiewski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013; 30:388. doi: 10.1007/s12032-012-0388-4.
20. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46:399–424. doi: 10.1080/00273171.2011.568786.